{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-25-000022","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.670349+00:00","generated_at":"2026-05-16T15:42:23.612736+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Avalo posts updated investor presentation; no specific new data disclosed","bullets":["Company filed 8-K announcing updated investor presentation posted on its website.","Presentation is a corporate overview focused on IL-1β therapies pipeline.","No financial results, trial data, or guidance changes included in the filing text.","Presentation will be used in meetings with investors going forward."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-25-000022","json":"https://secwatch.observer/filing/0001534120-25-000022.json","markdown":"https://secwatch.observer/filing/0001534120-25-000022.md","text":"https://secwatch.observer/filing/0001534120-25-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412025000022/0001534120-25-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412025000022/avtx-20251202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:42:23.612736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}